SAN DIEGO, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that John Turanin, vice president and general manager, Zogenix technologies, is scheduled to make a presentation that highlights successful repositioning of injectable sumatriptan for migraine with a novel needle-free delivery technology at the 2 nd Annual Drug Repositioning & Indications Discovery Conference, which is being held on October 23-24, 2012 in San Francisco, Calif. The case study demonstrates increased physician and patient adoption of a standard therapy when enhanced with the DosePro ® Needle-free Delivery System. Mr. Turanin's presentation, which will take place at 9:30 am PT on October 23, is a case study on Zogenix's first commercialized product utilizing DosePro technology, SUMAVEL ® DosePro ® (sumatriptan injection) Needle-free Delivery System, for the acute treatment of migraine and cluster headache. Mr. Turanin will examine the introduction of SUMAVEL DosePro to the U.S. market, including an analysis of the factors affecting the adoption of injectable products. For SUMAVEL DosePro, this included patient acceptance of a needle-free subcutaneous self-injection product despite the availability of oral or nasal alternatives. "In today's marketplace, unique delivery technology can be a competitive advantage and a key driver of product adoption. In developing SUMAVEL DosePro, we successfully leveraged the unique properties of the DosePro needle-free delivery system to reposition the under-utilized standard subcutaneous treatment for migraine, sumatriptan injection, into a novel treatment option that simplifies the patient experience. As a result, we have seen increased utilization of injectable triptans," stated Mr. Turanin. Turanin continued, "We view DosePro as an enabling delivery technology for both new and existing therapeutics that require or benefit from subcutaneous administration. It is particularly well suited for the delivery of highly viscous drug formulations such as biologics, which cannot be delivered via a traditional needle and syringe."